There are currently 87 clinical trials in Galveston, Texas looking for participants to engage in research studies. Trials are conducted at various facilities, including University of Texas Medical Branch, University of Texas Medical Branch at Galveston, Univ TX Galveston Med Branch and The University of Texas Medical Branch. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
The Protrieve PROTECTOR Study
NCT06495996
Recruiting
The Protrieve PROTECTOR Study is a prospective, single-arm, multicenter study of the Protrieve Sheath.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/24/2025
Locations: University of Texas Medical Branch, Galveston, Texas
Conditions: Venous Thromboembolism, Deep Venous Thrombosis
Register for Updates
A Study of Nipocalimab in Pregnancies at Risk for Severe Hemolytic Disease of the Fetus and Newborn (HDFN)
NCT05912517
Recruiting
The purpose of this study is to assess the effectiveness of nipocalimab when compared to placebo in decreasing the risk of fetal anemia (a condition in which a baby's red blood cell volume falls below normal levels while the baby is developing in the womb) with live neonates in pregnant participants at risk for severe hemolytic disease of the fetus and newborn.
Gender:
FEMALE
Ages:
Between 18 years and 45 years
Trial Updated:
06/20/2025
Locations: University Of Texas Medical Branch At Galveston, Galveston, Texas
Conditions: Hemolytic Disease of the Fetus and Newborn
Register for Updates
Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
NCT04704661
Recruiting
The dose escalation phase of this trial identifies the safety, side effects and best dose of ceralasertib (AZD6738) when given in combination with trastuzumab deruxtecan (DS-8201a) in treating patients with solid tumors that have a change (mutation) in the HER2 gene or protein and have spread to other places in the body (advanced). The dose expansion phase (phase Ib) of this trial compares how colorectal and gastroesophageal cancers with HER2 mutation respond to treatment with a combination of c... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/18/2025
Locations: University of Texas Medical Branch, Galveston, Texas
Conditions: Advanced Colorectal Carcinoma, Advanced Gastroesophageal Junction Adenocarcinoma, Advanced Malignant Solid Neoplasm, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Metastatic Gastroesophageal Junction Adenocarcinoma, Metastatic Malignant Solid Neoplasm, Stage III Colorectal Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8, Unresectable Colorectal Carcinoma, Unresectable Gastroesophageal Junction Adenocarcinoma, Unresectable Malignant Solid Neoplasm, Advanced Breast Carcinoma, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Advanced Colon Carcinoma, Advanced Endometrial Carcinoma, Advanced Gastric Carcinoma, Advanced Salivary Gland Carcinoma, Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8, Stage III Colon Cancer AJCC v8, Stage III Major Salivary Gland Cancer AJCC v8, Stage IV Colon Cancer AJCC v8, Stage IV Major Salivary Gland Cancer AJCC v8, HER2-Positive Breast Carcinoma, Malignant Hepatobiliary Neoplasm, Metastatic Colon Carcinoma, Metastatic Colorectal Carcinoma, Metastatic Endometrial Carcinoma, Metastatic Gastric Carcinoma, Metastatic Salivary Gland Carcinoma, Unresectable Breast Carcinoma, Unresectable Colon Carcinoma, Unresectable Endometrial Carcinoma, Unresectable Gastric Carcinoma, Unresectable Salivary Gland Carcinoma, Stage III Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8, Stage IV Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8
Register for Updates
ELEVATE, a Registry of Patients With Acute Hepatic Porphyria (AHP)
NCT04883905
Recruiting
This global patient registry is being conducted to characterize the natural history and real-world clinical management of patients with AHP, and to further characterize the real-world safety and effectiveness of givosiran and other approved AHP therapies.
Gender:
ALL
Ages:
12 years and above
Trial Updated:
06/16/2025
Locations: Clinical Trial Site, Galveston, Texas
Conditions: Acute Hepatic Porphyria
Register for Updates
Benralizumab Airway Remodeling Study in Severe Eosinophilic Asthmatics
NCT03953300
Recruiting
The purpose of the study is to evaluate effect of benralizumab on structural and lung function changes in severe eosinophilic asthmatics. Changes will be assessed over 48 week treatment period in patients with persistent symptoms despite standard therapy of inhaled corticosteroids (ICS) plus long acting B2-agonist (LABA) with or without additional controller medication. Patients who complete treatment will enter 4 weeks follow-up period.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
06/13/2025
Locations: Research Site, Galveston, Texas
Conditions: Asthma
Register for Updates
Non-Invasive Preeclampsia Screening and Biobank
NCT06643741
Recruiting
Women pregnant between 11-14 weeks gestation will be enrolled with blood samples collected to evaluate for preeclampsia.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
06/11/2025
Locations: University of Texas Medical Branch, Galveston, Texas
Conditions: Preeclampsia (PE)
Register for Updates
Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer
NCT03488693
Recruiting
The purpose of this study is to compare the effects on low risk breast cancer receiving usual care that includes regional radiation therapy, with receiving no regional radiation therapy. Researchers want to see if not giving this type of radiation treatment works as well at preventing breast cancer from coming back.
Gender:
FEMALE
Ages:
35 years and above
Trial Updated:
06/10/2025
Locations: University of Texas Medical Branch, Galveston, Texas
Conditions: Breast Cancer
Register for Updates
Understanding the Effects of Transcutaneous Auricular Neurostimulation for Treatment of Chronic Pain
NCT05555485
Recruiting
The purpose of the study is to find out how a stimulation device worn on the ear works. This device is thought to stimulate nerves in the area around the ear to change the signals in the brain. The device has been shown to reduce pain and to reduce the symptoms of withdrawal. The investigator will also investigate changes in the way each participant perceive sensations of pressure and heat. The participant will be asked to reduce the amount of pain medication that they take. Then, the participan... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
06/05/2025
Locations: University of Texas Medical Branch, Galveston, Texas
Conditions: Opioid Withdrawal, Analgesia
Register for Updates
JAGUAR Trial: ObJective Analysis to GaUge EVAR Outcomes Through Randomization
NCT05064540
Recruiting
Prospective, randomized, multi-center study designed to evaluate the outcomes of commercially available contemporary EVAR in a real-world population. Patients will be randomized into two device cohorts and compared across the primary endpoints. Patients will be followed procedurally to discharge, at 1, 6, 12 months and annually through to 5 years (total follow-up commitment).
Gender:
ALL
Ages:
21 years and above
Trial Updated:
06/05/2025
Locations: The University of Texas Medical Branch at Galveston, Galveston, Texas
Conditions: AAA, AAA - Abdominal Aortic Aneurysm
Register for Updates
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
NCT05879926
Recruiting
This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among premenopausal, early- stage breast cancer (EBC) patients with estrogen receptor (ER)-positive, HER2-negative tumors and 21-gene recurrence score (RS) between 16-25 (for pN0 patients) and 0-25 (for pN1 patients).
Gender:
FEMALE
Ages:
Between 18 years and 60 years
Trial Updated:
06/04/2025
Locations: University of Texas Medical Branch, Galveston, Texas
Conditions: Breast Cancer
Register for Updates
Cardiogenic Shock Working Group Registry
NCT04682483
Recruiting
The Cardiogenic Shock Working Group is a multicenter registry where we collect de-identified clinical variables from the medical records and follow-up phone calls of shock patients from multiple institutions and centralize this data to a single registry for analysis of clinical outcomes.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/03/2025
Locations: University of Texas Medical Branch, Galveston, Texas
Conditions: Cardiogenic Shock
Register for Updates
Primary Subtalar Arthrodesis for Calcaneal Fractures
NCT06249126
Recruiting
Management of severe injuries to the heel (displaced intra-articular calcaneus fractures) continues to be a major challenge for orthopedic surgeons. Previous studies have demonstrated poor outcomes, and results show that patients experience long-term pain and decreased quality of life postoperatively. Poor outcomes are driven by pain, in particular, which is linked to post-traumatic subtalar arthritis.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/02/2025
Locations: The University of Texas Medical Branch, Galveston, Texas
Conditions: Calcaneus Fracture
Register for Updates